To require the guidance of the Food and Drug Administration on reducing the risk of human immunodeficiency virus (HIV), hepatitis A, and hepatitis B transmission by blood and blood products (including the donor history questionnaire) to be based on an individual risk assessment of sexual behaviors upon which all donors are evaluated equally, without regard to sexual orientation or gender identity, and for other purposes.
About This Bill
Committee
Latest Action · September 4, 2020
Referred to the House Committee on Energy and Commerce.
Science in Blood Donation Act of 2020
This bill requires the Food and Drug Administration (FDA) to revise its guidance on reducing the risk of transmitting by blood transfusion human immunodeficiency virus, hepatitis A, and hepatitis B.
Specifically, the FDA shall update its guidance to remove recommendations to not receive blood donations from a man who had sex with another man in the past three months. The FDA shall also remove recommendations to not receive blood donations from a woman who in the last three months had sex with such a man.
The FDA's updated guidance shall be based on an individual risk assessment of sexual behaviors that evaluate all donors equally without regard to sexual orientation or gender identity.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.